289 related articles for article (PubMed ID: 18793787)
1. Generation of functionally active HIV-1 specific CD8+ CTL in intestinal mucosa following mucosal, systemic or mixed prime-boost immunization.
Belyakov IM; Ahlers JD; Nabel GJ; Moss B; Berzofsky JA
Virology; 2008 Nov; 381(1):106-15. PubMed ID: 18793787
[TBL] [Abstract][Full Text] [Related]
2. Gender differences in human immunodeficiency virus type 1-specific CD8 responses in the reproductive tract and colon following nasal peptide priming and modified vaccinia virus Ankara boosting.
Peacock JW; Nordone SK; Jackson SS; Liao HX; Letvin NL; Yafal AG; Gritz L; Mazzara GP; Haynes BF; Staats HF
J Virol; 2004 Dec; 78(23):13163-72. PubMed ID: 15542668
[TBL] [Abstract][Full Text] [Related]
3. A novel functional CTL avidity/activity compartmentalization to the site of mucosal immunization contributes to protection of macaques against simian/human immunodeficiency viral depletion of mucosal CD4+ T cells.
Belyakov IM; Isakov D; Zhu Q; Dzutsev A; Berzofsky JA
J Immunol; 2007 Jun; 178(11):7211-21. PubMed ID: 17513770
[TBL] [Abstract][Full Text] [Related]
4. Simultaneous approach using systemic, mucosal and transcutaneous routes of immunization for development of protective HIV-1 vaccines.
Belyakov IM; Ahlers JD
Curr Med Chem; 2011; 18(26):3953-62. PubMed ID: 21824096
[TBL] [Abstract][Full Text] [Related]
5. Efficient CD8+ T cell response to the HIV-env V3 loop epitope from multiple virus isolates by a DNA prime/vaccinia virus boost (rWR and rMVA strains) immunization regime and enhancement by the cytokine IFN-gamma.
Gómez CE; Abaitua F; Rodríguez D; Esteban M
Virus Res; 2004 Sep; 105(1):11-22. PubMed ID: 15325077
[TBL] [Abstract][Full Text] [Related]
6. A novel candidate HIV vaccine vector based on the replication deficient Capripoxvirus, Lumpy skin disease virus (LSDV).
Shen YJ; Shephard E; Douglass N; Johnston N; Adams C; Williamson C; Williamson AL
Virol J; 2011 May; 8():265. PubMed ID: 21624130
[TBL] [Abstract][Full Text] [Related]
7. Mucosal Priming with a Recombinant Influenza A Virus-Vectored Vaccine Elicits T-Cell and Antibody Responses to HIV-1 in Mice.
Wang J; Shu T; Deng W; Zheng Y; Liao M; Ye X; Han L; He P; Zheng X; Li T; Feng Y; Hu F; Li P; Sun C; Chen L; Li F; Feng L
J Virol; 2021 May; 95(12):. PubMed ID: 33789991
[TBL] [Abstract][Full Text] [Related]
8. Prime-Boost Immunization Eliminates Metastatic Colorectal Cancer by Producing High-Avidity Effector CD8
Xiang B; Baybutt TR; Berman-Booty L; Magee MS; Waldman SA; Alexeev VY; Snook AE
J Immunol; 2017 May; 198(9):3507-3514. PubMed ID: 28341670
[TBL] [Abstract][Full Text] [Related]
9. Virus-like vaccines against HIV/SIV synergize with a subdominant antigen T cell vaccine.
Schwerdtfeger M; Andersson AC; Neukirch L; Holst PJ
J Transl Med; 2019 May; 17(1):175. PubMed ID: 31126293
[TBL] [Abstract][Full Text] [Related]
10. Induction of HIV immunity in the genital tract after intranasal delivery of a MVA vector: enhanced immunogenicity after DNA prime-modified vaccinia virus Ankara boost immunization schedule.
Gherardi MM; Pérez-Jiménez E; Nájera JL; Esteban M
J Immunol; 2004 May; 172(10):6209-20. PubMed ID: 15128809
[TBL] [Abstract][Full Text] [Related]
11. Improving recombinant MVA immune responses: potentiation of the immune responses to HIV-1 with MVA and DNA vectors expressing Env and the cytokines IL-12 and IFN-gamma.
Abaitua F; Rodríguez JR; Garzón A; Rodríguez D; Esteban M
Virus Res; 2006 Mar; 116(1-2):11-20. PubMed ID: 16214252
[TBL] [Abstract][Full Text] [Related]
12. Prime-boost immunization schedules based on influenza virus and vaccinia virus vectors potentiate cellular immune responses against human immunodeficiency virus Env protein systemically and in the genitorectal draining lymph nodes.
Gherardi MM; Nájera JL; Pérez-Jiménez E; Guerra S; García-Sastre A; Esteban M
J Virol; 2003 Jun; 77(12):7048-57. PubMed ID: 12768024
[TBL] [Abstract][Full Text] [Related]
13. First-in-Human Evaluation of the Safety and Immunogenicity of an Intranasally Administered Replication-Competent Sendai Virus-Vectored HIV Type 1 Gag Vaccine: Induction of Potent T-Cell or Antibody Responses in Prime-Boost Regimens.
Nyombayire J; Anzala O; Gazzard B; Karita E; Bergin P; Hayes P; Kopycinski J; Omosa-Manyonyi G; Jackson A; Bizimana J; Farah B; Sayeed E; Parks CL; Inoue M; Hironaka T; Hara H; Shu T; Matano T; Dally L; Barin B; Park H; Gilmour J; Lombardo A; Excler JL; Fast P; Laufer DS; Cox JH;
J Infect Dis; 2017 Jan; 215(1):95-104. PubMed ID: 28077588
[TBL] [Abstract][Full Text] [Related]
14. Mucosal HIV-1 pox virus prime-boost immunization induces high-avidity CD8+ T cells with regime-dependent cytokine/granzyme B profiles.
Ranasinghe C; Turner SJ; McArthur C; Sutherland DB; Kim JH; Doherty PC; Ramshaw IA
J Immunol; 2007 Feb; 178(4):2370-9. PubMed ID: 17277143
[TBL] [Abstract][Full Text] [Related]
15. IL-4 and IL-13 mediated down-regulation of CD8 expression levels can dampen anti-viral CD8⁺ T cell avidity following HIV-1 recombinant pox viral vaccination.
Wijesundara DK; Jackson RJ; Tscharke DC; Ranasinghe C
Vaccine; 2013 Sep; 31(41):4548-55. PubMed ID: 23933364
[TBL] [Abstract][Full Text] [Related]
16. Induction of mucosal and systemic antibody and T-cell responses following prime-boost immunization with novel adjuvanted human immunodeficiency virus-1-vaccine formulations.
Cristillo AD; Ferrari MG; Hudacik L; Lewis B; Galmin L; Bowen B; Thompson D; Petrovsky N; Markham P; Pal R
J Gen Virol; 2011 Jan; 92(Pt 1):128-40. PubMed ID: 21169215
[TBL] [Abstract][Full Text] [Related]
17. Impact of vaccine-induced mucosal high-avidity CD8+ CTLs in delay of AIDS viral dissemination from mucosa.
Belyakov IM; Kuznetsov VA; Kelsall B; Klinman D; Moniuszko M; Lemon M; Markham PD; Pal R; Clements JD; Lewis MG; Strober W; Franchini G; Berzofsky JA
Blood; 2006 Apr; 107(8):3258-64. PubMed ID: 16373659
[TBL] [Abstract][Full Text] [Related]
18. Prime-boost vaccination using recombinant Mycobacterium bovis BCG and recombinant vaccinia virus DIs harboring HIV-1 CRF01_AE gag in mice: influence of immunization routes.
Promkhatkaew D; Matsuo K; Pinyosukhee N; Thongdeejaroen W; Leang-Aramgul P; Sawanpanyalert P; Warachit P
Southeast Asian J Trop Med Public Health; 2009 Mar; 40(2):273-81. PubMed ID: 19323012
[TBL] [Abstract][Full Text] [Related]
19. Optimized Mucosal Modified Vaccinia Virus Ankara Prime/Soluble gp120 Boost HIV Vaccination Regimen Induces Antibody Responses Similar to Those of an Intramuscular Regimen.
Jones DI; Pollara JJ; Johnson-Weaver BT; LaBranche CC; Montefiori DC; Pickup DJ; Permar SR; Abraham SN; Maddaloni M; Pascual DW; Staats HF
J Virol; 2019 Jul; 93(14):. PubMed ID: 31068425
[TBL] [Abstract][Full Text] [Related]
20. An experimental prime-boost regimen leading to HIV type 1-specific mucosal and systemic immunity in BALB/c mice.
Brühl P; Kerschbaum A; Eibl MM; Mannhalter JW
AIDS Res Hum Retroviruses; 1998 Mar; 14(5):401-7. PubMed ID: 9546799
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
